PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Committee Opinion No. 717: Sulfonamides, Nitrofurantoin, and Risk of Birth Defects.

Abstract The evidence regarding an association between the nitrofuran and sulfonamide classes of antibiotics and birth defects is mixed. As with all patients, antibiotics should be prescribed for pregnant women only for appropriate indications and for the shortest effective duration. During the second and third trimesters, sulfonamides and nitrofurantoins may continue to be used as first-line agents for the treatment and prevention of urinary tract infections and other infections caused by susceptible organisms. Prescribing sulfonamides or nitrofurantoin in the first trimester is still considered appropriate when no other suitable alternative antibiotics are available. Pregnant women should not be denied appropriate treatment for infections because untreated infections can commonly lead to serious maternal and fetal complications.
PMID
Related Publications

Exposure to nitrofurantoin during early pregnancy and congenital malformations: a systematic review and meta-analysis.

Nitrofurantoin and congenital abnormalities.

Antibacterial medication use during pregnancy and risk of birth defects: National Birth Defects Prevention Study.

ACOG Committee Opinion No. 494: Sulfonamides, nitrofurantoin, and risk of birth defects.

Committee Opinion No. 717 Summary: Sulfonamides, Nitrofurantoin, and Risk of Birth Defects.

Authors

Mayor MeshTerms
Keywords
Journal Title obstetrics and gynecology
Publication Year Start




PMID- 28832488
OWN - NLM
STAT- MEDLINE
DA  - 20170823
DCOM- 20170908
LR  - 20170908
IS  - 1873-233X (Electronic)
IS  - 0029-7844 (Linking)
VI  - 130
IP  - 3
DP  - 2017 Sep
TI  - Committee Opinion No. 717: Sulfonamides, Nitrofurantoin, and Risk of Birth
      Defects.
PG  - e150-e152
LID - 10.1097/AOG.0000000000002300 [doi]
AB  - The evidence regarding an association between the nitrofuran and sulfonamide
      classes of antibiotics and birth defects is mixed. As with all patients,
      antibiotics should be prescribed for pregnant women only for appropriate
      indications and for the shortest effective duration. During the second and third 
      trimesters, sulfonamides and nitrofurantoins may continue to be used as
      first-line agents for the treatment and prevention of urinary tract infections
      and other infections caused by susceptible organisms. Prescribing sulfonamides or
      nitrofurantoin in the first trimester is still considered appropriate when no
      other suitable alternative antibiotics are available. Pregnant women should not
      be denied appropriate treatment for infections because untreated infections can
      commonly lead to serious maternal and fetal complications.
CN  - Committee on Obstetric Practice
LA  - eng
PT  - Journal Article
PT  - Practice Guideline
PL  - United States
TA  - Obstet Gynecol
JT  - Obstetrics and gynecology
JID - 0401101
RN  - 0 (Anti-Infective Agents, Urinary)
RN  - 0 (Sulfonamides)
RN  - 927AH8112L (Nitrofurantoin)
SB  - AIM
SB  - IM
MH  - Abnormalities, Drug-Induced/*epidemiology
MH  - Anti-Infective Agents, Urinary/*adverse effects
MH  - Female
MH  - Humans
MH  - Limb Deformities, Congenital/chemically induced/*epidemiology
MH  - Nitrofurantoin/*adverse effects
MH  - Obstetrics
MH  - Pregnancy
MH  - Risk Factors
MH  - Societies, Medical
MH  - Sulfonamides/*adverse effects
MH  - United States
EDAT- 2017/08/24 06:00
MHDA- 2017/09/09 06:00
CRDT- 2017/08/24 06:00
AID - 10.1097/AOG.0000000000002300 [doi]
AID - 00006250-201709000-00048 [pii]
PST - ppublish
SO  - Obstet Gynecol. 2017 Sep;130(3):e150-e152. doi: 10.1097/AOG.0000000000002300.